Association of SGLT2 inhibitors with incident cancer
Authors:
- 24 October 2024
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 50 (6) , 101585
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysisJournal of Endocrinological Investigation, 2024
- SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 DiabetesDrug Safety, 2023
- Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based studyCancer Medicine, 2023
- Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trialsDiabetes Research and Clinical Practice, 2023
- Association between COVID-19 pandemic and mental disorders in spouses of intensive care unit patientsIntensive Care Medicine, 2022
- Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studiesPharmacoepidemiology and Drug Safety, 2022
- Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparatorsPharmacoepidemiology and Drug Safety, 2022
- Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A ReviewReviews in Endocrine and Metabolic Disorders, 2021
- SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance DatabaseThe Journal of Clinical Pharmacology, 2020
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trialsDiabetologia, 2017